Perceptive Advisors’s Cullinan Therapeutics CGEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.77M Buy
+426,478
New +$6.33M 0.12% 86
2025
Q2
– Sell
-80,100
Closed -$606K – 90
2025
Q1
$606K Buy
+80,100
New +$769K 0.02% 80
2024
Q3
– Sell
-749,916
Closed -$13.1M – 112
2024
Q2
$13.1M Buy
+749,916
New +$16M 0.32% 63

Other funds holding CGEM

Perceptive Advisors's CGEM Position: Q2 2026 in Review

Perceptive Advisors opened a new position in Cullinan Therapeutics (CGEM) in Q2 2026: 426,478 shares worth $7.77M. The stake represents 0.12% of the portfolio and ranks #86 among its holdings. This is a return to the name: Perceptive Advisors previously reported a position in CGEM as recently as Q1 2025.

Perceptive Advisors first reported a position in CGEM in Q2 2024 and has held it in 3 quarters since. The position peaked at $13.1M in Q2 2024. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Perceptive Advisors held 426,478 shares of Cullinan Therapeutics worth $7.77M as of Q2 2026.
  • Cullinan Therapeutics was a new Perceptive Advisors position in Q2 2026.
  • Cullinan Therapeutics made up 0.12% of Perceptive Advisors's portfolio in Q2 2026, its #86 holding.
  • Perceptive Advisors first reported a position in Cullinan Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • Perceptive Advisors's Cullinan Therapeutics position peaked at $13.1M in Q2 2024.
  • 183 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.